title: [Isolation and biological characteristics of mesenchymal stem cells derived from human placenta decidua basalis].
abstract: Comparing to bone marrow mesenchymal stem cells (MSCs), placenta-derived MSCs have the advantages of adequate sources, low immunogenicity, little risk of viral contamination, and no ethical controversy, and thus possess a better prospect for clinical application. Placental tissue not only includes chorionic and amniotic, but also contains decidua basalis which locate in the maternal placenta surface. The biological characteristics of MSCs isolated from decidua basalis have not been well studied. This study was aimed to investigate the biologic characteristics of placenta decidua basalis-derived MSC from placenta decidua basalis (DB) by enzymatic digestion. Short tandem repeats (STR) test was used to identify the cells derived from the maternal placenta surface. Growth rate of decidua basalis mesenchymal stem cells (DB-MSC) was measured by MTT. Cell cycle and cell phenotype were detected by flow cytometry. Inducing differentiation was used to evaluate multipotency of DB-MSC. For testing the immunosuppression of DB-MSC, they were co-cultured with peripheral blood mononuclear cells (PBMNC) stimulated by phytohemagglutinin (PHA) and then IFN-γ in the co-cultured media was quantified by ELISA. The results showed that the cells were derived from the maternal placenta by STR analysis. DB-MSC showed typical fibroblast morphology in the culture and were positive for the MSC surface markers: CD90, CD73, CD105, CD44 and negative for CD45, CD11b, and CD34. DB-MSC underwent osteogenic, adipogenic and chondrogenic differentiation in inducing medium. DB-MSC could inhibit the secretion of IFN-γ by PBMNC. It is concluded that the cells are isolated from placenta decidua basalis and possess the basic characteristics of MSC. DB-MSC can be an important maternal autologous MSC and may be a safe and effective treatment for immune system diseases, which makes the DB-MSC as an important source of autologous MSC from mother. DB-MSC can be safely for the treatment of the mother's immune system diseases.
authors.affiliation: Chinese Academy of Medical Sciences, Tianjin, China.
authors.forename: Zhi-Bo
authors.initials: ZB
authors.lastname: Han
authors.forename: You-Wei
authors.initials: YW
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Chi
authors.forename: Zhou-Xin
authors.initials: ZX
authors.lastname: Yang
authors.forename: Yue-Ru
authors.initials: YR
authors.lastname: Ji
authors.forename: Lei
authors.initials: L
authors.lastname: Meng
authors.forename: Ping
authors.initials: P
authors.lastname: Yang
authors.forename: Zhong-Chao
authors.initials: ZC
authors.lastname: Han
mesh_terms: D002454:Cell Differentiation; D002478:Cells, Cultured; D003656:Decidua / Q000166:cytology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D010920:Placenta / Q000166:cytology*; D011247:Pregnancy